ArticleScientific reports2013
A polymorphism of HMGA1 is associated with increased risk of metabolic syndrome and related components.
Article in Scientific reports, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 2 syntheses or guidelines pooled it, 53 citations in OpenAlex.
- HMGA1 variant IVS5-13insC is associated with insulin resistance and type 2 diabetes: an updated meta-analysis.African health sciences · 2018Pooled it
- The Association between HMGA1 rs146052672 Variant and Type 2 Diabetes: A Transethnic Meta-Analysis.PloS one · 2015Pooled it
- Effect of Mediterranean Diet and Antioxidant Formulation in Non-Alcoholic Fatty Liver Disease: A Randomized Study.Nutrients · 2017Trial
- Article
- Prognostic Significance ofInternational journal of molecular sciences · 2022Article
- Insulin Resistance and Cancer: In Search for a Causal Link.International journal of molecular sciences · 2021Review
- Western diet leads to aging-related tumorigenesis via activation of the inflammatory, UPR, and EMT pathways.Cell death & disease · 2021Article
- Clinical Effectiveness and Safety of Once-Weekly GLP-1 Receptor Agonist Dulaglutide as Add-On to Metformin or Metformin Plus Insulin Secretagogues in Obesity and Type 2 Diabetes.Journal of clinical medicine · 2021Article
- Mediterranean Diet Nutrients to Turn the Tide against Insulin Resistance and Related Diseases.Nutrients · 2020Review
- MicroRNA-1281 as a Novel Circulating Biomarker in Patients With Diabetic Retinopathy.Frontiers in endocrinology · 2020Article
- Long-Term Effectiveness of Liraglutide for Weight Management and Glycemic Control in Type 2 Diabetes.International journal of environmental research and public health · 2019Article
- First Trimester Combined Test (FTCT) as a Predictor of Gestational Diabetes Mellitus.International journal of environmental research and public health · 2019Article
- Long-Term Effectiveness and Safety of SGLT-2 Inhibitors in an Italian Cohort of Patients with Type 2 Diabetes Mellitus.Journal of diabetes research · 2019Observational
- Genome-Wide Interaction and Pathway Association Studies for Body Mass Index.Frontiers in genetics · 2019Article
- Insulin Receptor Isoforms in Cancer.International journal of molecular sciences · 2018Review
- Diabetes, Obesity, and Breast Cancer.Endocrinology · 2018Review
- Cross-talk among HMGA1 and FoxO1 in control of nuclear insulin signaling.Scientific reports · 2018Article
- HMGA1 is a novel transcriptional regulator of the FoxO1 gene.Endocrine · 2018Article
- Postpartum glucose intolerance: an updated overview.Endocrine · 2018Review
- Type 2 Diabetes Mellitus and Cardiovascular Disease: Genetic and Epigenetic Links.Frontiers in endocrinology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors at 6 institutions in 4 countries.
Funding
Abstract
The metabolic syndrome (MetS) is a common disorder, where systemic insulin-resistance is associated with increased risk for type 2 diabetes (T2D) and cardiovascular disease. Identifying genetic traits influencing risk and progression of MetS is important. We and others previously reported a functional HMGA1 gene variant, rs146052672, predisposing to T2D. Here we investigated the association of rs146052672 variant with MetS and related components. In a case-control study from Italy and Turkey, increased risk of MetS was seen among carriers of the HMGA1 variant. In the larger Italian cohort, this variant positively correlated with BMI, hyperglycemia and insulin-resistance, and negatively correlated with serum HDL-cholesterol. Association between rs146052672 variant and MetS occurred independently of T2D, indicating that HMGA1 gene defects play a pathogenetic role in MetS and other insulin-resistance-related conditions. Overall, our results indicate that the rs146052672 variant represents an early predictive marker of MetS, as well as a predictive tool for therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.